tbuckley/cabot-search huggingface dataset:
Bodily pain among a cohort of breast cancer survivors.
Authors: Carolyn E. Behrendt, Joanne E. Mortimer
Journal: Journal of Clinical Oncology (2015)

e20623 Background: Breast cancer survivors often report bodily pain, but longitudinal data on this problem are lacking. Methods: Subjects were female, English-speaking survivors who completed symptom questionnaires at pre-treatment baseline and at follow-up (at 6 and/or 12 months). Subjects rated bodily pain in past month as none, very mild, mild, moderate, severe, very severe (level 1-6). Changes from baseline in bodily pain rating, clustered by subject, were entered into a generalized estimating equation model adjusted for body mass index (BMI) and demographics. Factors tested for association with change in pain were: time since baseline, bodily pain rating at baseline, having received chemotherapy, and having received endocrine therapy. Significance was adjusted (Holm-Bonferroni) for testing these 4 hypotheses. Results: Subjects (n = 126, median age at baseline 53.0 (5th-95th percentile range 33.4-65.7) years) returned data at month 6 only (n = 35), month 12 only (n = 17), or both times (n = 74). At baseline, bodily pain was at least moderate in 55/126 (43.7%) subjects. At follow-up, bodily pain was at least one level worse than baseline in 27.5% of subjects at 6 months and in 16.5% at 12 months. It was necessary to adjust the multivariate model for BMI, education (less than high school), and race/ethnicity (Asian/Pacific Islander) but not for age, menopausal or marital status. According to the model, for a non-Asian patient of BMI 30, bodily pain at 6 months was 1.01 (95% CI 0.53-1.49) level worse than before treatment. Such a change was less marked with greater bodily pain at baseline (-0.48 per step increase, 95% CI -0.63 - -0.33, p < 0.0001) and with time since baseline (-0.45 for 12 months vs 6 months, 95% CI -0.71 - -0.18, p < 0.003) but did not vary with receipt of chemotherapy or endocrine therapy. Conclusions: For over one quarter of breast cancer survivors, bodily pain is worse after breast cancer treatment. This symptom occurs regardless of type of therapy and often improves with time.
Differential Safety Between Top-Ranked Cancer Hospitals and Their Affiliates for Complex Cancer Surgery
Authors: Jessica R. Hoag, Benjamin J. Resio, Andres F. Monsalve, Alexander S. Chiu, Lawrence B. Brown, Jeph Herrin, Justin D. Blasberg, Anthony W. Kim, Daniel J. Boffa
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Leading cancer hospitals have increasingly shared their brands with other hospitals through growing networks of affiliations. However, the brand of top-ranked cancer hospitals may evoke distinct reputations for safety and quality that do not extend to all hospitals within these networks. <h3>Objective</h3> To assess perioperative mortality of Medicare beneficiaries after complex cancer surgery across hospitals participating in networks with top-ranked cancer hospitals. <h3>Design, Setting, and Participants</h3> A cross-sectional study was performed of the Centers for Medicare &amp; Medicaid Services 100% Medicare Provider and Analysis Review file from January 1, 2013, to December 31, 2016, for top-ranked cancer hospitals (as assessed by<i>U.S. News and World Report</i>) and affiliated hospitals that share their brand. Participants were 29 228 Medicare beneficiaries older than 65 years who underwent complex cancer surgery (lobectomy, esophagectomy, gastrectomy, colectomy, and pancreaticoduodenectomy [Whipple procedure]) between January 1, 2013, and October 1, 2016. <h3>Exposures</h3> Undergoing complex cancer surgery at a top-ranked cancer hospital vs an affiliated hospital. <h3>Main Outcomes and Measures</h3> Risk-adjusted 90-day mortality estimated using hierarchical logistic regression and comparison of the relative safety of hospitals within each cancer network estimated using standardized mortality ratios. <h3>Results</h3> A total of 17 300 patients (59.2%; 8612 women and 8688 men; mean [SD] age, 74.7 [6.2] years) underwent complex cancer surgery at 59 top-ranked hospitals and 11 928 patients (40.8%; 6287 women and 5641 men; mean [SD] age, 76.2 [6.9] years) underwent complex cancer surgery at 343 affiliated hospitals. Overall, surgery performed at affiliated hospitals was associated with higher 90-day mortality (odds ratio, 1.40; 95% CI, 1.23-1.59;<i>P</i> &lt; .001), with odds ratios that ranged from 1.32 (95% CI, 1.12-1.56;<i>P</i> = .001) for colectomy to 2.04 (95% CI, 1.41-2.95;<i>P</i> &lt; .001) for gastrectomy. When the relative safety of each top-ranked cancer hospital was compared with its collective affiliates, the top-ranked hospital was safer than the affiliates in 41 of 49 studied networks (83.7%; 95% CI, 73.1%-93.3%). <h3>Conclusions and Relevance</h3> The likelihood of surviving complex cancer surgery appears to be greater at top-ranked cancer hospitals compared with the affiliated hospitals that share their brand. Further investigation of performance across trusted cancer networks could enhance informed decision making for complex cancer care.
Lowering the P Value Threshold—Reply
Authors: Cole Wayant, Jared Scott, Matt Vassar
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy.
Authors: Claire Tissot, Anne Claire Toffart, Stephanie Villar, Pierre Jean Souquet, Patrick Merle, Denis Moro-Sibilot, Maurice Pérol, Jiri Zavadil, Christian Brambilla, Magali Olivier, Sebastien Couraud
Journal: Journal of Clinical Oncology (2015)

11046 Background: Plasma circulating free DNA (cfDNA) has raised interest in oncology because it has been shown to contain tumor DNA and may thus be used as liquid biopsy. In non-small cell lung cancer, cfDNA quantification has been proposed to be useful as prognosis biomarker and for monitoring. However, available studies are limited and need to be confirmed. Our objective was to assess the predictive and prognostic value of plasma cfDNA concentration in a large series of patients with non-small cell lung cancer and treated with a standard chemotherapy regimen. Methods: Our study included samples from lung cancer patients who have been recruited in the French PHARMACOGENOSCAN study. CfDNA of 218 patients has been extracted and quantified by fluorometry before and after 2 or 3 cycles of platinum-based chemotherapy. The correlations between baseline or post-chemotherapy concentrations and treatment response assessed by RECIST 1.0 criteria or patient survival were analyzed. Results: 176 patients had stage IV disease and 42 patients had stage IIIb disease. We found that patients with high cfDNA concentration (highest tertile) at baseline had a significant poorer median progression free and overall survivals (OS) than those with lower concentrations (lowest and middle tertile) (10 months (95% CI 10.7-13.9) versus 14.2 months (95%CI 12.6-15.8) for median OS respectively, (P 0.001)). In multivariate analysis, increased baseline concentration in cfDNA was significantly associated to OS independently of Performance Status at diagnosis, stage, age, and response rate. However, we did not find any association between cfDNA concentration and response to treatment. Conclusions: These results show that cfDNA may be a useful non-invasive marker for prognosis assessment in NSCLC. However, total concentration of cfDNA is not a good biomarker to assess chemotherapy response.
From Distrust to Building Trust in Clinician-Organization Relationships
Authors: Mary Jane Kornacki, Jack Silversin, Dave A. Chokshi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT-374-Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-G+CD4+ regulatory T -cell population
Authors: Wafa Khamri, Cathrin Gudd, Marigona Krasniqi, Rooshi Nathwani, Arjuna Singanayagam, Sofia Azam, Tong Liu, Fanny Lebosse, Naveenta Kumar, Rocio Castro Seoane, Thomas Barbera, Trevor Askwith, Christopher Weston, Mark Thursz, Charalambos Antoniades
Journal: Journal of Hepatology (2019)
CRISPR/Cas9 PIG-A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs
Authors: Tae-Hoon Shin, Eun Jung Baek, Marcus A. F. Corat, Shirley Chen, Jean-Yves Metais, Aisha A. AlJanahi, Yifan Zhou, Robert E. Donahue, Kyung-Rok Yu, Cynthia E. Dunbar
Journal: Blood (2019)
Correction to: Rapid turnover of life-cycle-related genes in the brown algae
Authors: Agnieszka P. Lipinska, Martha L. Serrano-Serrano, Alexandre Cormier, Akira F. Peters, Kazuhiro Kogame, J. Mark Cock, Susana M. Coelho
Journal: Genome biology (2019)

Following publication of the original article [1], it was noticed that the author names were published with initials instead of full names. The article [1] has been updated.
Pemetrexed-induced interstitial lung disease.
Authors: Bindu Adhikari, Raj Man Dongol, Dipti Baral, Binay Kumar Shah
Journal: Journal of Clinical Oncology (2015)

e18522 Background: Interstitial lung disease (ILD) is an uncommon side effect of pemetrexed. We conducted this study to identify different factors associated with pemetrexed-induced ILD. Methods: We conducted a retrospective study of the records of adverse events in the FDA MedWatch database with pemetrexed therapy from Feb 2004 till Feb 2014. We searched the database for keywords such as interstitial lung disease, pneumonitis, dyspnea, chest pain, cough, lung infiltrate, acute lung injury, respiratory failure, and acute respiratory distress syndrome. We requested for the actual MedWatch reports of these cases. Then, we identified cases diagnosed with drug induced ILD and analyzed them further. Results: We identified 44 cases of pemetrexed-induced ILD. Among them, 33 patients with Non-small Cell Lung Cancer (NSCLC), 10 patients with Malignant Pleural Mesothelioma (MPM) and 1 patient with undocumented diagnosis developed ILD. Patients received a median of 3 (1-11) doses of pemetrexed prior to ILD diagnosis. Median interval between first dose and ILD diagnosis was 70 (1-403) days. Case fatality rate was 45.5%. Pemetrexed was used as monotherapy in 18.4% of the cases and 81.6% had received concomitant chemotherapy mostly with cisplatin (18 patients), carboplatin (10 patients), bevacizumab (9 patients) and erlotinib (5 patients). Among these patients, 34% were smoker, 22.7% had history of radiotherapy, 15.5 % had history of asbestos exposure, 11.3 % had history of COPD, and 6.8% had pre-existing ILD. Majority of the patients were Asians (59%). Conclusions: Although uncommon, interstitial lung disease is a potentially fatal toxicity of pemetrexed. Physicians should be vigilant about possibility of pemetrexed-induced ILD in patients with history of COPD, smoking, asbestos exposure, radiation exposure or pre-existing ILD.
FRI-045-Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival
Authors: Carla Fiorella Murillo Perez, Pol Boudes, Alexandra (Sasha) Steinberg, Monika Varga, Yun-Jung Choi, Harry Janssen, Aliya Gulamhusein, Gideon Hirschfield, Bettina Hansen
Journal: Journal of Hepatology (2019)
Depression in primary care: part 1—screening and diagnosis
Authors: Erin K Ferenchick, Parashar Ramanuj, Harold Alan Pincus
Journal: BMJ (2019)

Abstract Depression is a common and heterogeneous condition with a chronic and recurrent natural course that is frequently seen in the primary care setting. Primary care providers play a central role in managing depression and concurrent physical comorbidities, and they face challenges in diagnosing and treating the condition. In this two part series, we review the evidence available to help to guide primary care providers and practices to recognize and manage depression. In this first of two reviews, we outline an approach to screening and diagnosing depression in primary care that evaluates current evidence based guidelines and applies the recommendations to clinical practice. The second review presents an evidence based approach to the treatment of depression in primary care, detailing the recommended lifestyle, drug, and psychological interventions at the individual level. It also highlights strategies that are being adopted at an organizational level to manage depression more effectively in primary care.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Authors: Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña, Yohann Loriot, Mohammad Afshar, Vincent Miller, Fanny Wunder, Catherine Bresson, Jean-François Martini, Jacques Raynaud, John Mendelsohn, Gerald Batist, Amir Onn, Josep Tabernero, Richard L. Schilsky, Vladimir Lazar, J. Jack Lee, Razelle Kurzrock
Journal: Nature Medicine (2019)
THU-402-Tailored message interventions using social marketing approach versus traditional message for increasing participation in viral hepatitis screening for Japanese workers
Authors: Masaaki Korenaga, Tatsuya lde, Chieko Ooe, Keiko Kamimura, Keiko Korenaga, Tatusya Ide, Takako Inoue, Jun Fukuyoshi
Journal: Journal of Hepatology (2019)
THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy
Authors: Luisa Pasulo, Martina Gambato, Angiola Spinetti, Roberta D’ambrosio, Massimo Puoti, Alessia Ciancio, Vito Di Marco, Vincenza Calvaruso, Colombatto Piero, Maurizia Brunetto, Monica Schiavini, Paolo Sacchi, Roberto Gulminetti, Giada Carolo, Piergiorgio Scotton, Caterina Pozzan, Maria Vinci, Mauro Vigano, Andrea Lombardi, Salvatore Lobello, Massimo Giovanni Zuin, Alessio Aghemo, Maria Grazia Rumi, Vinicio Manfrin, Caterina Uberti-Foppa, Sandro Panese, Veronica Paon, Angelo Pan, Ombretta Spinelli, Antonella d’Arminio Monforte, Agostino Colli, Giancarlo Spinzi, Francesco Paolo Russo, Liliana Chemello, Valter Vincenzi, Paolo Antonio Grossi, Elisabetta Buscarini, Alessandro Soria, Barbara Menzaghi, Monia Mendeni, Roberta Soffredini, Maria Colpani, Serena Zaltron, ANDREA Gori, Alessia Giorgini, Giuliana Cologni, Fabio Cartabellotta, Lorenzo Difrancesco, Irene Cacciola, Antonio Albanese, Maria Antonietta Di Rosolini, Antonio Di Giacomo, Andrea Capretti, massimo Memoli, Luisa Cavalletto, Franco Capra, Alberto Colombo, Clara Dibenedetto, Carlo Federico Magni, Franco Noventa, Pietro Lampertico, Francesco Castelli, Alfredo Alberti, Stefano Fagiuoli
Journal: Journal of Hepatology (2019)
Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab.
Authors: Rodrigo Ramella Munhoz, Taha Merghoub, Ryan O Emerson, Margaret K. Callahan, Jedd D. Wolchok, Michael Andrew Postow
Journal: Journal of Clinical Oncology (2015)

9075 Background: Blockade of the programmed death-1 (PD-1) receptor results in impressive activity in patients (pts) with metastatic melanoma (MM). Mechanisms of antitumor effect are not fully understood but may be associated with the degree of T cell receptor (TCR) repertoire clonality in tumor infiltrating lymphocytes (TIL). We hypothesized that differences among multiple tumors in the same patient may be reflected in heterogeneity of TCR repertoire clonality in TIL. We tested this hypothesis using TCR sequencing in pts with MM treated with pembrolizumab. Methods: Post-treatment samples were obtained from different lesions at the same time points. TCR repertoire quantification was performed using high-throughput sequencing of the rearranged TCR β-chain genes; these were amplified and sequenced using the survey ImmunoSeq assay in a multiplexed PCR method using primers to TCR Vβ and Jβ gene segments. Productive TCR sequences were used to obtain a clonality metric, and frequency of each T cell clone was obtained by comparing the number of reads generated by each unique CDR3 sequence. The proportion of TIL was determined using quantitative immunohistochemistry. Variations in proportion of TIL and clonality between samples were analyzed using ANOVA test. Tests were performed in duplicate. Results: Eight tumors from two pts receiving pembrolizumab (Four from pt A and four from pt B, obtained 2 and 4 months after treatment initiation, respectively) were analyzed. Significant intrapatient intertumoral heterogeneity in TCR repertoire was observed (pt A: p = 0.000153 and p = 0.013/pt B: p = 0.00083 and p = 9.01E-07 for differences in proportion of TIL and clonality, respectively). There was a high correlation between duplicates (r2 = 0.86- > 0.99), suggesting these findings were not the result of experimental variation. Conclusions: Our data suggest significant intrapatient intertumoral heterogeneity in the proportion of TIL and clonality of the TCR repertoire at the same post-treatment timepoint. Caution should be exercised in interpreting the results of TCR analyses from single tumor biopsies in patients treated with checkpoint blockade.
FRI-386-Impact of acute-on-chronic liver failure on survival after liver transplantation
Authors: Sebastián Marciano, Liliana P Rojas-Saunero, Ezequiel Mauro, Maria C Torres, Maria N Gutiérrez-Acevedo, Carla Bermudez, Juan M Díaz, Adrián Narvaez, Jorge Ortíz, Melisa Dirchwolf, Florencia Pollarsky, Adrián C Gadano
Journal: Journal of Hepatology (2019)
Clinical significance of co-expression of E-cadherin and vimentin in invasive breast cancer.
Authors: Nami Yamashita, Eriko Tokunaga, Yuka Inoue, Kimihiro Tanaka, Yuichiro Nakashima, Koji Ando, Kippei Ogaki, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2015)

e22013 Background: E-cadherin has been categorized as a tumor suppressor and its downregulation is considered to occur in the process of epithelial-mesenchymal transition (EMT). E-cadherin and vimentin are now regarded as major and conventional canonical markers of EMT. We previously reported that the elevated expression of vimentin contributes to the aggressive phenotype in invasive breast cancer. However, the role of E-cadherin in breast cancer biology might be unclear and more complex. The aim of this study is to reveal the clinical importance of the expression of E-cadherin and vimentin in breast cancer. Methods: The E-cadherin and vimentin protein expression were evaluated by immunohistochemistry (IHC) in 176 invasive breast cancer samples. Among these, E-cadherin and vimentin expression were evaluated in the set of primary breast cancer and metastatic lymph nodes in 65 cases. Results: The positive vimentin expression was highly correlated with poor disease-free survival (DFS) and overall survival (OS) (p = 0.019 and p = 0.0044), however, the E-cadherin expression alone did not correlate with prognosis. Interestingly, Both E-cadherin and vimentin positive tumor had the worst DFS and OS among all breast cancer (p = 0.03 and p = 0.0089). Vimentin expression was highly correlated between primary tumors and metastatic lymph nodes. However, E-cadherin expression levels were significantly elevated in metastatic lymph nodes (p = 0.0017), Co-expression of E-cadherin and vimentin in the metastatic lymph nodes also showed worst DFS and OS (p = 0.12 and p = 0.027). Conclusions: Co-expression of E-cadherin and vimentin seems to be associated with the most aggressive phenotype and poor prgnosis in breast cancer, and positive E-cadherin expression may not always play roles for tumor suppression.
PS-211-Liver transplantation for HCC: Applicability and performance of the AFP score in real life. The French organization for organ sharing (ABM) experience
Authors: Christophe DUVOUX, Mathilde Petiet, Nadia Oubaya, Daniel Cherqui, Georges-Philippe Pageaux, Ephrem Salamé, Sylvie Radenne, Pauline Houssel-Debry, Philippe Bachellier, Martine Neau Cransac, Claire Francoz, Fabrice Muscari, Jean Gugenheim, CONTI Filomena, vanlemmens claire, duman mirela, Sebastien Dharancy
Journal: Journal of Hepatology (2019)
Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance
Authors: Yali Wu, Yali Liu, Junfeng Lu, Zhenhuan Cao, Yi Jin, Lina Ma, Nan Geng, Shan Ren, Yanhong Zheng, Chengli Shen, Xinyue Chen
Journal: Clinical Gastroenterology and Hepatology (2019)

Hepatitis B surface antigen (HBsAg) seroclearance has been recommended as an optimal endpoint of antiviral treatment by the latest chronic hepatitis B management guideline.1 However, few reports investigated the durability of response after HBsAg seroclearance, because of a lower HBsAg seroclearance rate and the difficulty of obtaining a sufficient number of samples for analysis. Our center has made a long-term commitment to investigate the personalized antiviral therapy for chronic hepatitis B. More than 300 patients achieved HBsAg seroclearance by interferon (IFN)-based antiviral treatment. In this study, the durability and the effects of hepatitis B virus (HBV) surface antibody (Anti-HBs) level on relapse after HBsAg seroclearance were investigated.